Enable Injections designs and produces on-body delivery systems that allow patients to self-administer large amounts of medication.
Enable Injections designs, manufactures, and sells wearable delivery devices for injectable drugs. The Enable Injections products can deliver drugs directly from standard vials supplied by all pharmaceutical companies, can reconstitute powdered drugs into liquids as a part of the injection procedure, can inject very viscous drugs, and can inject up to 20 ml. Such products are called bolus injection systems. No other existing drug delivery device can accomplish all of these tasks. For inquiries, telephone and contact numbers are used.Approximately 900 new drugs are being developed that may require bolus injection technology like that being developed by Enable Injections. The total market is expected to reach $8 billion within ten years. Partisan principals have supplied 10% of the seed capital to Enable Injections. It also delivers a controlled flow of up to 50 ml of a biologic through an automatically inserted needle. Enable Injections also offers a version of the drug delivery platform that may connect to smartphones via Bluetooth. It also utilizes any standard container closure system, including syringes or vials; automatically warms and can automatically mix lyophilized solutions.Enable Injections was founded in 2010 and is headquartered in Cincinnati, Ohio, USA.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 25, 2018 | Series B | $50M | 1 | Sanofi | — | Detail |